Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04926181 · ClinicalTrials.gov registry record · Phase 2
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
A Phase 2 study, sponsored by Rahul Aggarwal.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04926181 is a Phase 2 study that was terminated before completion, run by Rahul Aggarwal. The registered enrollment target is 2 participants.
The verdict
NCT04926181, a Phase 2 study, was terminated before completion, sponsored by Rahul Aggarwal.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small cell neuroendocrine prostate cancer, there is persistent AR expression observed in the majority of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) biopsies. This indicates that epigenetic dysregulation leads to reprogramming away from an AR-driven transcriptional program. Therefore, continuation of AR blockade in the form of apalutamide may provide additive benefit compared to immune checkpoint blockade alone. The investigators hypothesize that the combination of apalutamide plus cetrelimab will achieve a clinically significant composite response rate with sufficient durability of response in mCRPC patients with evidence of treatment-emergent small cell neuroendocrine prostate cancer
Interventions
- DRUG Apalutamide
- BIOLOGICAL Cetrelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04926181
The ClinicalTrials.gov registry entry for NCT04926181 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rahul Aggarwal, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apalutamide is the first listed.
NCT04926181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04926181 about?
NCT04926181 is a clinical study titled "Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer". Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small cell neuroendocrine prostate cancer, there is persistent AR expression observed in the majority of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) biopsies. This indicates that epigeneti...
What is the current status of trial NCT04926181?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-03-16. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT04926181?
The interventions under investigation include: Apalutamide (DRUG), Cetrelimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04926181?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.